Clinical trials: Advanced RCC
Carcinoma, Renal Cell
Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
To study the absorption, distribution, metabolism and excretion of GW786034, and the absorption of a single IV dose of GW786034
- Trial name
- NCT00478725
- Testing
- GW786034, oral, GW786034, IV, GW786034, radiolabeled oral
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumor, Lymphoma
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
DS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is available.
- Trial name
- NCT01588678
- Testing
- DS-3078a
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Renal Cell Carcinoma (RCC), Metastatic Renal Cell Carcinoma (mRCC)
PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk
This phase 2 trial aims to test the feasibility and efficiency of PET/CT-directed treatment interruption strategy in metastatic renal cell carcinoma patients with IMDC favorable/intermediate risk who achieve complete (CMR) or…
- Trial name
- Perfumer (NCT07175480)
- Testing
- Intermittent PD-1/PD-L1 ICI + VEGFR-TKI
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jinling Hospital, China
Renal Cell Cancer
Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
The purpose of this study is to determine whether an increase in the dose of sorafenib when given over five instead of 7 days/week, will result in an improvement of the response rate (degree of shrinkage of your cancer) and an…
- Trial name
- NCT01189370
- Testing
- sorafenib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Kansas Medical Center
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Kidney, Cancer
Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma
The purpose of this study is to evaluate a therapy combining the established FUNIL regimen with Thalidomide. We want to see how well the therapy works, if it can be easily done, and how well the body handles the treatment.
- Trial name
- NCT00277017
- Testing
- 5-Flourouracil, Interferon-a, IL-2 and Thalidomide
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- New Mexico Cancer Research Alliance
Carcinoma, Renal Cell
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Research Questions: To understand the clinical outcomes of patients treated with sunitinib in first line and axitinib in second line in a real world setting as therapies for metastatic and/or advanced renal cell carcinoma (mRCC).
- Trial name
- NCT04033991
- Testing
- Sunitinib, Axitinib
- Where
- United Kingdom
- Volunteers
- 684 people
- Sponsor
- Pfizer
Neoplasms, Renal Cell Carcinoma
Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland
Patient receiving sunitinib according the clinician's independent decision as first-line treatment of advanced renal cell carcinoma (RCC) will be asked for informed consent.
- Trial name
- NCT00980213
- Testing
- sunitinib
- Where
- 5 sites in Finland
- Volunteers
- 80 people
- Sponsor
- Pirkko-Liisa Kellokumpu-Lehtinen
Metastatic Renal Cell Carcinoma
INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma
This study aims to report the effects of immediate or delayed exercise training on patients with advanced or metastatic renal cell carcinoma who are receiving nivolumab and ipilimumab.
- Trial name
- INTERVAL (NCT03692338)
- Testing
- Exercise
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Duke University
Colorectal Cancer, Renal Cell Carcinoma
Study of DC-CTL Combined With CIK for Advanced Solid Tumor
Background: Combinations of Dendritic and Cytokine-induced Killer Cells (DC-CIK) and Cytokine-induced Killer Cells (CIK) treatment may enhance the immune response and stop cancer cells from growing.
- Conditions
- Colorectal Cancer, Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Lung Cancer
- Trial name
- NCT03047525
- Testing
- Cytokine-induced Killer Cells
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xiaoyi Huang
Advanced Solid Tumors
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors.
- Trial name
- NCT02460224
- Testing
- LAG525, PDR001
- Where
- 24 sites in United States, Australia and 10 more
- Volunteers
- 490 people
- Sponsor
- Novartis Pharmaceuticals
Renal Malignant Tumor
Predictive Imaging Features in Renal Cell Carcinoma
The investigators aimed to evaluate the role of some findings that can be detected in preoperative radiological imaging of kidney masses in predicting locally advanced disease.
- Trial name
- NCT05042089
- Testing
- No intervention will be applied.
- Where
- Turkey (Türkiye)
- Volunteers
- 92 people
- Sponsor
- Ankara Yildirim Beyazıt University
Advanced Solid Tumors
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.
- Trial name
- NCT02301117
- Testing
- TAS-102
- Where
- 14 sites in United States, Czechia and 1 more
- Volunteers
- 43 people
- Sponsor
- Taiho Oncology, Inc.
Breast Cancer, Renal Cell Carcinoma
Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma
MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells…
- Trial name
- MARIO-3 (NCT03961698)
- Testing
- IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel
- Where
- 24 sites in United States
- Volunteers
- 91 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Epithelial Ovarian Cancer, Non-small Cell Lung Cancer
ITIL-306 in Advanced Solid Tumors
ITIL-306-201 is a phase 1a/1b, multicenter, clinical trial evaluating the safety and feasibility of ITIL-306 in adult participants with advanced solid tumors whose disease has progressed after standard therapy.
- Conditions
- Epithelial Ovarian Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT05397093
- Testing
- ITIL-306
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Instil Bio
Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
This phase Ib/II trial studies the side effects and best dose of plinabulin in combination with radiation therapy and immunotherapy in patients with select cancers that have spread to other places in the body (advanced) after…
- Conditions
- Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT04902040
- Testing
- Atezolizumab, Avelumab, Durvalumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung
A Study of Oncobax®-AK in Patients With Advanced Solid Tumors
Akkermansia muciniphila is a naturally occurring bacterium found in the healthy human gastrointestinal tract. Analysis of the gut microbiota of NSCLC or RCC patients shows that the presence of Akkermansia is associated with the…
- Trial name
- NCT05865730
- Testing
- Live Bacterial Product - Akkermansia muciniphila
- Where
- 4 sites in Belgium, France
- Volunteers
- 122 people
- Sponsor
- EverImmune
Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them. PURPOSE: Randomized phase II trial to determine the effectiveness of monoclonal antibody therapy in…
- Trial name
- NCT00019539
- Testing
- bevacizumab, thalidomide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)